CEO Pierre Belichard tells Scrip that the French biotech has enough cash and assets to prosper alone but it is also weighing up a reverse merger that would give Enterome a listing on the NASDAQ.

Microbiome modulators, known mainly for development in infectious and gastrointestinal diseases, could prove an asset in oncology thanks to the work of biotechs.

In this roundup feature focusing on the developments in digital health, we highlight the key news and announcements from July.

In this installment of our VC Playbook series, In Vivo sits down with Isabelle de Cremoux, CEO of Seventure. The company has been a pioneer investor in the microbiome space, which Cremoux believes has now reached a turning point.